Clifford Capital Partners LLC Has $16.75 Million Stock Position in GSK plc (NYSE:GSK)

Clifford Capital Partners LLC lifted its stake in GSK plc (NYSE:GSK - Free Report) by 14.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 409,669 shares of the pharmaceutical company's stock after acquiring an additional 51,378 shares during the period. GSK makes up 3.3% of Clifford Capital Partners LLC's portfolio, making the stock its 12th largest holding. Clifford Capital Partners LLC's holdings in GSK were worth $16,747,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Eastern Bank acquired a new position in shares of GSK in the third quarter valued at $26,000. Concord Wealth Partners boosted its position in shares of GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company's stock valued at $32,000 after acquiring an additional 547 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in GSK in the second quarter valued at about $37,000. Fortitude Family Office LLC acquired a new position in GSK in the third quarter worth about $42,000. Finally, PrairieView Partners LLC bought a new position in GSK during the second quarter worth about $47,000. Institutional investors own 15.74% of the company's stock.

Insider Activity

In related news, major shareholder Plc Gsk purchased 2,791,930 shares of the business's stock in a transaction dated Friday, September 27th. The shares were bought at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the purchase, the insider now directly owns 16,775,691 shares in the company, valued at $134,205,528. This trade represents a 19.97 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. 10.00% of the stock is currently owned by insiders.

GSK Price Performance

GSK traded up $0.31 during midday trading on Wednesday, hitting $34.33. The company had a trading volume of 2,958,971 shares, compared to its average volume of 4,153,231. GSK plc has a twelve month low of $32.83 and a twelve month high of $45.92. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The firm's 50-day simple moving average is $37.73 and its 200-day simple moving average is $40.17. The company has a market capitalization of $71.15 billion, a PE ratio of 22.09, a P/E/G ratio of 1.31 and a beta of 0.66.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be given a dividend of $0.3928 per share. The ex-dividend date is Friday, November 15th. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.58%. This is an increase from GSK's previous quarterly dividend of $0.38. GSK's payout ratio is presently 99.35%.

Analyst Upgrades and Downgrades

GSK has been the topic of several analyst reports. Jefferies Financial Group lowered GSK from a "buy" rating to a "hold" rating and lowered their price objective for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Guggenheim lowered GSK from a "buy" rating to a "neutral" rating in a research note on Thursday, October 31st. Deutsche Bank Aktiengesellschaft cut GSK from a "buy" rating to a "hold" rating in a report on Friday, November 15th. Argus upgraded shares of GSK to a "strong-buy" rating in a research report on Wednesday, August 7th. Finally, Barclays raised shares of GSK to a "hold" rating in a report on Tuesday, August 27th. Seven equities research analysts have rated the stock with a hold rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, GSK has a consensus rating of "Moderate Buy" and an average target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.